Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Minocycline plus low-dose glucocorticoids vs medium-dose glucocorticoids in bullous pemphigoid
ChiCTR2200060454Phase 4Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of minocycline in Bullous Pemphigoid (BP) (2 arms), sponsored by Peking University First Hospital. Primary endpoints: Treatment effect and Adverse reactions. Planned start May 2022; status: not yet recruiting.
02
Drugs
minocycline
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on ChiCTR2200060454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060454.